** Shares in Straumann STMN.S are seen up around 3% in pre-market indications after the Swiss dental implant maker's Q3 results came in slightly ahead of consensus expectations
** The company reported sales on Wednesday at 602.2 million Swiss francs ($759.30 million), slightly above a Vara consensus estimate at 600.6 million
** J.P. Morgan points to better than expected acceleration in the U.S. and a robust EMEA region performance
** The company also announced new partnerships in its orthodontics business, which JPM sees as a pragmatic response to cut costs to protect margins
** Up to the previous session's close, shares were down 23.4% YTD
($1 = 0.7931 Swiss francs)
(Reporting by Cian Muenster)
((Cian.muenster@thomsonreuters.com))